September 16, 20240 citations

Figure S4 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

SLSun Min Lim TFToshio Fujino CKChulwon Kim

Key Points

Key points are not available for this paper at this time.

Abstract

Supplementary Figure 4. Western blot of Ba/F3 cells with the EGFR 19Del/T790M/C797S mutation after BBT-176 treatment, alone and combined with cetuximab.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Lim et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522c56 https://doi.org/10.1158/1078-0432.27032014.v1

Ask AI

Helpful

Bookmark

View Full Paper

September 16, 20240 citations

Figure S4 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

View Full Paper

SLSun Min Lim TFToshio Fujino CKChulwon Kim

Key Points

Key points are not available for this paper at this time.

Abstract

Supplementary Figure 4. Western blot of Ba/F3 cells with the EGFR 19Del/T790M/C797S mutation after BBT-176 treatment, alone and combined with cetuximab.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Lim et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522c56 https://doi.org/10.1158/1078-0432.27032014.v1

Ask AI

Helpful

Bookmark

View Full Paper